var data={"title":"Strongyloidiasis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Strongyloidiasis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/strongyloidiasis/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dd><a href=\"https://www.uptodate.com/contents/strongyloidiasis/contributors\" class=\"contributor contributor_credentials\">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/strongyloidiasis/contributors\" class=\"contributor contributor_credentials\">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/strongyloidiasis/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/strongyloidiasis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 26, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strongyloidiasis is caused by infection with <em>Strongyloides stercoralis</em>. Manifestations of infection can range from asymptomatic eosinophilia in the immunocompetent host to disseminated disease with septic shock in the immunocompromised host.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strongyloidiasis is endemic in rural areas of tropical and subtropical regions and occurs sporadically in temperate areas (Appalachia and southern Europe) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In tropical and subtropical regions, the overall regional prevalence may exceed 25 percent. The highest rates of infection in the United States are among residents of the southeastern states [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/3,4\" class=\"abstract_t\">3,4</a>] and among individuals who have been in endemic areas (including immigrants, refugees, travelers, and military personnel) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Transmission of strongyloidiasis in long-term care settings has also been described [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/4,7\" class=\"abstract_t\">4,7</a>].</p><p>Immunosuppressed individuals are at risk for developing <em>Strongyloides</em> hyperinfection syndrome. In addition, solid organ transplant recipients receiving organs from donors with epidemiologic risk for latent <em>Strongyloides</em> infection are at risk for donor-derived strongyloidiasis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"#H10\" class=\"local\">'Role of immunosuppression'</a> below and <a href=\"#H24\" class=\"local\">'Prevention'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">LIFE CYCLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The infection begins when human skin contacts filariform larvae (the infective larval stage) of <em>S. stercoralis</em>, which are found in soil or other materials contaminated with human feces (<a href=\"image.htm?imageKey=ID%2F87284\" class=\"graphic graphic_figure graphicRef87284 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. The filariform larvae penetrate the skin and migrate hematogenously to the lungs where they penetrate into the alveolar air sacs. The larvae then ascend the tracheobronchial tree and are swallowed.</p><p>The larvae mature into adult worms that burrow into the mucosa of the duodenum and jejunum. Adult worms may live for up to five years. The adult female produces eggs, from which noninfectious larvae (rhabditiform larvae) develop within the lumen of the gastrointestinal tract. The rhabditiform larvae are generally passed in the feces. The cycle from dermal penetration to appearance of larvae in the stool requires approximately three to four weeks.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Autoinfection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast with other helminthic parasites, <em>S. stercoralis</em> can complete its life cycle entirely within the human host [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/12\" class=\"abstract_t\">12</a>]. As a result, the burden of adult worms in infected humans can increase substantially through a cycle of autoinfection. During autoinfection, the rhabditiform larvae mature into filariform larvae within the gastrointestinal tract. The filariform larvae can then penetrate the perianal skin or colonic mucosa to complete the cycle of autoinfection. Larval transformation within the gastrointestinal tract may also be accelerated by constipation, diverticula, other conditions that reduce bowel motility, and steroid use.</p><p>Although autoinfection is limited by an intact immune response, a low level of autoinfection may permit the organism to persist for decades and cause clinical manifestations long after the initial infection [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/13\" class=\"abstract_t\">13</a>]. This has been observed in prisoners of war who were found to be infected more than 40 years after exposure in Thailand [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/14\" class=\"abstract_t\">14</a>]. However, in patients with depressed cell-mediated immunity, autoinfection may give rise to potentially fatal hyperinfection with disseminated disease [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/15,16\" class=\"abstract_t\">15,16</a>]. (See <a href=\"#H9\" class=\"local\">'Hyperinfection syndrome'</a> below.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most infected patients do not experience prominent symptoms. The most common manifestations are mild waxing and waning gastrointestinal, cutaneous, or pulmonary symptoms that persist for years; others simply have eosinophilia in the absence of symptoms.</p><p>Eosinophilia is not universally present in strongyloidiasis but may be the only clue that the patient harbors a parasitic infection. One report, for example, evaluated 128 Indochinese patients with eosinophilia, the cause of which was not apparent by routine screening [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/17\" class=\"abstract_t\">17</a>]. Intestinal parasitism with one or more organisms was responsible for the eosinophilia in 122; hookworm (55 percent) and <em>S. stercoralis</em> (38 percent) were the most common organisms.</p><p>However, eosinophilia may be suppressed or absent in disseminated disease because of concomitant pyogenic infection or steroid administration [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/18\" class=\"abstract_t\">18</a>]. The serum immunoglobulin (Ig)E concentration is often elevated in these settings [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Skin reactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. stercoralis</em> may produce cutaneous reactions when larvae penetrate the skin, sometimes termed ground itch [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/20,21\" class=\"abstract_t\">20,21</a>]. These reactions include inflammation, edema, petechiae, serpiginous or urticarial tracts, and severe pruritus. The feet are the most commonly affected site with initial infection, but dermal manifestations of primary infection rarely lead patients to seek medical attention.</p><p>With chronic infection, urticaria or pruritus can develop. In addition, the dermal migration of larvae may produce a distinctive eruption at other sites, most commonly on the buttocks. As larvae migrate, a raised, evanescent pink track develops; these lesions are known as larva currens (&quot;running&quot; larva) and are pathognomonic of strongyloidiasis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/22\" class=\"abstract_t\">22</a>]. Other skin lesions in chronic strongyloidiasis may include periumbilical purpura in disseminated infections [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/23\" class=\"abstract_t\">23</a>], nonpalpable purpura [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/24\" class=\"abstract_t\">24</a>], angioedema [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/25,26\" class=\"abstract_t\">25,26</a>], and erythroderma that mimics drug reaction [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Gastrointestinal symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The adult worms in the small bowel induce duodenitis, which can lead to upper abdominal pain [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/28,29\" class=\"abstract_t\">28,29</a>]. Patients may also experience diarrhea, anorexia, nausea, and vomiting. Epigastric pain may mimic a duodenal ulcer, except that food ingestion may aggravate the pain of strongyloidiasis. Chronic enterocolitis and malabsorption can result from a high intestinal worm burden.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Pulmonary manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The transpulmonary migration of larvae can produce dry cough, throat irritation, dyspnea, wheezing, and hemoptysis. A Loeffler's-like syndrome with eosinophilia is rarely observed.</p><p>Some patients with chronic strongyloidiasis experience repeated episodes of fever and mild pneumonitis, producing a picture that resembles recurrent bacterial pneumonia. Eosinophilia is often absent initially but may develop later in the infection. Treatment of the strongyloidiasis terminates the episodes of pneumonia.</p><p>Patients with chronic strongyloidiasis may also develop asthma that paradoxically worsens with corticosteroid use [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/30,31\" class=\"abstract_t\">30,31</a>] or dyspnea due to restrictive pulmonary disease [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/32\" class=\"abstract_t\">32</a>]. Strongyloidiasis can present as acute respiratory failure or pulmonary embolism [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Hyperinfection syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cycle of autoinfection can lead to the hyperinfection syndrome by greatly increasing the parasite burden. Autoinfection within the gastrointestinal tract begins when rhabditiform larvae transform into filariform larvae, which penetrate the intestinal wall to enter the bloodstream. The massive dissemination of filariform larvae to the lungs, liver, heart, central nervous system, and endocrine glands induces inflammation that may result in symptomatic dysfunction of these organs and even septic shock [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/15,34-36\" class=\"abstract_t\">15,34-36</a>]. (See <a href=\"#H3\" class=\"local\">'Life cycle'</a> above.)</p><p>The most common manifestations of the hyperinfection syndrome include [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/28,34,37\" class=\"abstract_t\">28,34,37</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea and vomiting</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anorexia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diarrhea</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abdominal pain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dyspnea</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wheezing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hemoptysis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cough</p><p/><p>The chest radiograph reveals pulmonary infiltrates that consist of foci of hemorrhage, pneumonitis, and edema (<a href=\"image.htm?imageKey=RADIOL%2F97783\" class=\"graphic graphic_diagnosticimage graphicRef97783 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/38\" class=\"abstract_t\">38</a>]. Rarely, adult parasites localize in the bronchial tree and lay eggs that develop into larvae in the airway. Bronchospasm frequently accompanies this manifestation of hyperinfection [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>The clinical findings in the hyperinfection syndrome may be attributable to the direct consequences of organ invasion by the filariform larvae or to secondary gram-negative bacteremia, pneumonia, or even meningitis due to bloodstream seeding originating from the gastrointestinal tract or lungs [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Eosinophilia may be absent when complications such as gram-negative bacteremia ensue [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/38\" class=\"abstract_t\">38</a>]. Mortality rates of 10 to &gt;80 percent have been reported in the hyperinfection syndrome. (See <a href=\"#H11\" class=\"local\">'Whom to test'</a> below.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Role of immunosuppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The likelihood of developing the hyperinfection syndrome is increased if cell-mediated immunity is impaired by congenital immunodeficiency, underlying malignancy, malnutrition, alcoholism, hematopoietic stem cell transplantation (HSCT), or the administration of corticosteroids or cytotoxic drugs [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/15,42-54\" class=\"abstract_t\">15,42-54</a>]. Even short courses of corticosteroids of 6 to 17 days have led to overwhelming hyperinfection and death [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/55\" class=\"abstract_t\">55</a>]. The pathophysiology underlying these risk factors, whether disease related or iatrogenically induced, is a compromised immune system leading to dysfunction of TH-2 helper cells [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/56\" class=\"abstract_t\">56</a>]. It is therefore important to detect and eradicate <em>Strongyloides</em> infection prior to initiation of immunosuppressive therapy. (See <a href=\"#H11\" class=\"local\">'Whom to test'</a> below.)</p><p>In comparison with steroids and cytotoxic agents, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> has activity against <em>Strongyloides</em> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/57\" class=\"abstract_t\">57</a>]. It is unknown, however, whether this effect is sufficient to reduce the risk of hyperinfection in patients receiving cyclosporine.</p><p>Underlying human T-lymphotropic virus type I (HTLV-I) infection is a significant risk factor for disseminated strongyloidiasis and treatment failure [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/58-60\" class=\"abstract_t\">58-60</a>]. Patients with HTLV-I infection have high levels of interferon-gamma production, which decreases the production of interleukin (IL)-4, IL-5, IL-13, and IgE, important molecules in host defense against <em>Strongyloides</em> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/19,61,62\" class=\"abstract_t\">19,61,62</a>]. Regulatory T cells may play a role in susceptibility to <em>Strongyloides</em> hyperinfection; among patients with HTLV-I and <em>Strongyloides</em> coinfection, regulatory T cell counts are increased and correlate with both low circulating eosinophil counts and reduced antigen-driven IL-5 production [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/63\" class=\"abstract_t\">63</a>].</p><p>Disseminated strongyloidiasis can occur in patients with AIDS [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/64,65\" class=\"abstract_t\">64,65</a>], but it occurs less frequently than in patients with HTLV-I and is much less common than might be predicted given the co-endemicity of the two infections. However, immune reconstitution may be a risk factor for disseminated strongyloidiasis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/66-68\" class=\"abstract_t\">66-68</a>] and HIV-infected patients may be at risk for <em>Strongyloides</em> treatment failure [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/69\" class=\"abstract_t\">69</a>].</p><p>Other conditions or medications may be associated with an increased risk of strongyloidiasis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypogammaglobulinemia [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/70,71\" class=\"abstract_t\">70,71</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anti&ndash;tumor necrosis factor receptor therapy [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/72,73\" class=\"abstract_t\">72,73</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organ transplantation from an uninfected donor to an infected recipient with previously subclinical infection that is unmasked by immunosuppression [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/74-76\" class=\"abstract_t\">74-76</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Organ transplantation from an infected donor to an uninfected recipient [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/54\" class=\"abstract_t\">54</a>]</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">WHOM TO TEST</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Testing for strongyloidiasis is appropriate for individuals in the following categories:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with clinical manifestations and epidemiologic exposure as described above (including unexplained eosinophilia, urticarial or serpiginous skin lesions, or pulmonary or gastrointestinal symptoms).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunosuppressed patients (steroid and other immunosuppressive treatments, human T-lymphotropic virus type I infection, hematologic malignancy, malnutrition, AIDS) with unexplained eosinophilia, history of characteristic skin lesions, or epidemiologic exposure [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/18,77\" class=\"abstract_t\">18,77</a>]. Transplant candidates should also be tested prior to immunosuppression if they have a potential exposure history [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymptomatic individuals such as immigrants, refugees, long-term travelers, or military personnel who have been in areas known to be endemic for strongyloidiasis, even if their last exposure was decades prior [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/5,79-82\" class=\"abstract_t\">5,79-82</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In endemic regions, patients with invasive infections caused by enteric organisms (especially systemic gram-negative bacterial infections) without an obvious cause [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/83,84\" class=\"abstract_t\">83,84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transplant donors from endemic areas; detection of donor strongyloides infection should prompt prophylaxis for recipients after transplantation [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"#H24\" class=\"local\">'Prevention'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of uncomplicated strongyloidiasis is usually made by detecting rhabditiform larvae in concentrated stool or via serologic methods. As noted above, larvae first appear in the stool three to four weeks after initial dermal penetration (<a href=\"image.htm?imageKey=ID%2F63898\" class=\"graphic graphic_picture graphicRef63898 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/85\" class=\"abstract_t\">85</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Detection of larvae</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Standard stool examination is notoriously insensitive for detecting <em>Strongyloides</em> (&lt;50 percent sensitivity) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/86\" class=\"abstract_t\">86</a>]. This is because larvae are excreted only intermittently, and many patients have a low burden of infectious organisms. Specialized tests on stool specimens, including the Baerman concentration technique, the Harada-Mori filter paper technique, and a modified agar plate method, can increase the yield, but even three or more stool examinations can fail to detect <em>Strongyloides</em> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/87,88\" class=\"abstract_t\">87,88</a>]. Of the specialized techniques, the agar plate method is used most commonly and is most sensitive [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/89\" class=\"abstract_t\">89</a>]. It involves inoculating agar plates with stool and incubating for two days at room temperature. Larvae crawl on the agar and spread bacteria in their paths, creating bacterial growth patterns on the agar surface. Larvae can be seen by macroscopic examination of the plates and their presence confirmed with formalin washing of the plate surface and examination of the sediment from the washing [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/90\" class=\"abstract_t\">90</a>].</p><p>Aspiration of duodenojejunal fluid or the use of a string test (Enterotest) is sometimes used to detect <em>Strongyloides</em> larvae in patients with negative stool samples [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/85\" class=\"abstract_t\">85</a>]. Alternatively, serologic testing may be helpful (see <a href=\"#H14\" class=\"local\">'Serology'</a> below).</p><p>In disseminated strongyloidiasis, filariform larvae can be found in stool, sputum, bronchoalveolar lavage fluid, pleural fluid, peritoneal fluid, and surgical drainage fluid [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/47,91-95\" class=\"abstract_t\">47,91-95</a>]. Sputum should also be examined for larvae if disseminated strongyloidiasis is suspected [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/93,95,96\" class=\"abstract_t\">93,95,96</a>]. For patients with rash, larvae may be visualized by skin biopsy.</p><p>Polymerase chain reaction (PCR) tests have also been developed for detection of <em>Strongyloides </em>in stool samples and have been found to be more sensitive and more reliable in detection of <em>S. stercoralis</em> compared with parasitological methods [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/97,98\" class=\"abstract_t\">97,98</a>]. However, PCR tests are not yet widely available.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Serology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnosis of strongyloidiasis by enzyme-linked immunosorbent assay (ELISA) has proven useful in immunocompetent individuals, both in symptomatic and asymptomatic strongyloidiasis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/99,100\" class=\"abstract_t\">99,100</a>]. The ELISA for detecting <em>S. stercoralis </em>infection detects immunoglobulin (Ig)G to filariform larvae. Negative test results in immunocompetent individuals decrease the likelihood that infection is present; however, some ELISA serologies run by commercial laboratories are of variable reliability. In addition, ELISA results can be falsely negative in immunocompromised hosts [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/96\" class=\"abstract_t\">96</a>]. False-positive results may occur in the presence of other helminth infections [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/90\" class=\"abstract_t\">90</a>].</p><p>The ELISA may be positive even when repeated examinations of stool samples have been unrevealing [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/101\" class=\"abstract_t\">101</a>]. However, ELISA can be falsely negative in immunocompromised hosts [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/96\" class=\"abstract_t\">96</a>]. In addition, some ELISA serologies run by commercial laboratories are of variable reliability.</p><p>In one study, two commercially available ELISAs (IVD-ELISA and Bordier-ELISA) were found to have sensitivity of 89 and 83 percent, respectively, and specificity of 97.2 percent for both in the diagnosis of intestinal strongyloidiasis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/102\" class=\"abstract_t\">102</a>].</p><p>Indirect immunofluorescence assays have also been developed, as has a gelatin particle agglutination test [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/103\" class=\"abstract_t\">103</a>]. A newer technique, luciferase immunoprecipitation system (LIPS), is another attractive alternative to ELISA-based methods [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/104\" class=\"abstract_t\">104</a>] but is not commercially available.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Endoscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Upper endoscopy is not usually needed to establish a diagnosis of strongyloidiasis. However, it may be performed in patients with gastrointestinal symptoms with unsuspected disease. Strongyloidiasis has a broad range of endoscopic features [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/105\" class=\"abstract_t\">105</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the duodenum, the findings included edema, brown discoloration of the mucosa, erythematous spots, subepithelial hemorrhages, and megaduodenum.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the colon, the findings include loss of vascular pattern, edema, aphthous ulcers, erosions, serpiginous ulcerations, and xanthoma-like lesions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the stomach, thickened folds and mucosal erosions are seen [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/106\" class=\"abstract_t\">106</a>].</p><p/><p>Larvae may be demonstrated on biopsies of the affected mucosa [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/18,107\" class=\"abstract_t\">18,107</a>].</p><p><em>Strongyloides</em> colitis can sometimes mimic ulcerative colitis, but distinctive features of the strongyloidiasis include skip pattern of the inflammation, distal attenuation of the disease, eosinophil-rich infiltrates, relatively intact crypt architecture, and frequent involvement of submucosa (<a href=\"image.htm?imageKey=ID%2F51753\" class=\"graphic graphic_picture graphicRef51753 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/108\" class=\"abstract_t\">108</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of strongyloidiasis includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ascariasis and hookworm &ndash; Strongyloidiasis, ascariasis, and hookworm can all cause nonspecific gastrointestinal <span class=\"nowrap\">and/or</span> pulmonary symptoms or chronic urticaria <span class=\"nowrap\">and/or</span> pruritus. In addition, all can be associated with eosinophilia in the presence or absence of other symptoms. Coinfection can occur; the diagnoses are distinguished by stool microscopy. (See <a href=\"topic.htm?path=approach-to-stool-microscopy\" class=\"medical medical_review\">&quot;Approach to stool microscopy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous larva migrans &ndash; The strongyloidiasis skin reaction known as larva currens must be distinguished from cutaneous larva migrans; both are associated with migratory serpiginous lesions that are erythematous, raised, and pruritic. The conditions usually can be distinguished clinically based on the speed of advancement; larva currens can progress approximately 1 cm in 5 minutes and 5 to 15 cm per hour, while the larval track of cutaneous larva migrans progresses approximately 1 to 2 cm per day. Additionally, larva currens is typically evanescent and pink whereas larva migrans is angry looking, red, and raised and typically persists for weeks. (See <a href=\"topic.htm?path=hookworm-related-cutaneous-larva-migrans\" class=\"medical medical_review\">&quot;Hookworm-related cutaneous larva migrans&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tropical filarial pulmonary eosinophilia &ndash; Disseminated strongyloidiasis may resemble tropical filarial pulmonary eosinophilia; symptoms include dry cough, wheeze, and fatigue. Tropical pulmonary eosinophilia is characterized by eosinophilia above <span class=\"nowrap\">3000/microL;</span> the diagnosis can be confirmed by filarial antibody titers. (See <a href=\"topic.htm?path=tropical-pulmonary-eosinophilia\" class=\"medical medical_review\">&quot;Tropical pulmonary eosinophilia&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Uncomplicated infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the past, thiabendazole was administered for uncomplicated infection. However, thiabendazole is now rarely used due to the availability of more efficacious and better tolerated medications. The treatment of choice for strongyloidiasis is <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> with <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> as an alternative [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/109-111\" class=\"abstract_t\">109-111</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Ivermectin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">Ivermectin</a> is usually administered as two single 200 <span class=\"nowrap\">mcg/kg</span> doses of ivermectin administered on two consecutive days [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/109,112\" class=\"abstract_t\">109,112</a>].</p><p>In a study of 88 patients with strongyloidiasis, 31 patients received thiabendazole 25 <span class=\"nowrap\">mg/kg/12</span> hours for three consecutive days; 22 patients received <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> 200 <span class=\"nowrap\">mcg/kg</span> as a single dose, and 35 patients received ivermectin for two consecutive days [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/110\" class=\"abstract_t\">110</a>]. The efficacy rates were 78, 77, and 100 percent in the thiabendazole, ivermectin single dose, and ivermectin two-dose regimens, respectively. Sixteen percent of patients taking thiabendazole experienced side effects in contrast with 3 percent in the combined ivermectin groups.</p><p>In immigrants from areas of Africa endemic for loiasis, patients should be screened to exclude high levels of <em>Loa loa </em>microfilaremia because administration of <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> to highly microfilaremic subjects can precipitate life-threatening encephalopathy.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Albendazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> (400 mg by mouth on empty stomach twice daily for three to seven days) also has activity against <em>Strongyloides</em> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/113,114\" class=\"abstract_t\">113,114</a>]. In varied studies, the efficacy of albendazole has been lower than that of <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a>, with a mean of 60 percent effectiveness for three days of albendazole versus 92 percent for ivermectin [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/115\" class=\"abstract_t\">115</a>]. One study of 42 Thai patients with chronic strongyloidiasis noted a cure rate of 90 percent following a single dose of ivermectin compared with 50 percent for seven days of albendazole 800 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/116\" class=\"abstract_t\">116</a>].</p><p class=\"headingAnchor\" id=\"H2967228659\"><span class=\"h3\">Other</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Moxidectin is a veterinary drug that may be effective for treatment of <em>Strongyloides.</em> In a randomized trial including 127 patients with strongyloidiasis that compared the efficacy and safety of moxidectin (8 mg) with <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> (200 <span class=\"nowrap\">mcg/kg),</span> cure rates were 93.7 and 95.2 percent, respectively [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/117\" class=\"abstract_t\">117</a>]. Non-inferiority could not be demonstrated because of underpowering of the study, but no side effects were observed; further studies are needed to determine whether moxidectin might have a role as a treatment alternative to ivermectin.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Disseminated disease/hyperinfection syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal treatment of disseminated disease and hyperinfection is uncertain, as data are limited. In immunocompromised patients with disseminated disease, reduction of immunosuppressive therapy, if possible, is an important adjunct to any anthelminthic therapy. In such cases, it is also usually necessary to prolong or repeat <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> therapy, although there is no generally agreed upon regimen.</p><p>Some experts give five to seven days of <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> in disseminated disease or combine ivermectin with <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> until the patient responds. Often the duration of treatment is determined clinically; daily ivermectin should be administered until symptoms resolve and daily stool examinations have been negative for at least two weeks (one autoinfection cycle) or longer if patient remains immunosuppressed [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/118\" class=\"abstract_t\">118</a>].</p><p>The optimal treatment of critically ill patients with the hyperinfection syndrome is uncertain; data regarding the ideal dose, duration, and route of therapy is limited. In patients with hyperinfection strongyloidiasis who were not able to receive oral therapy due to ileus or obtundation, alternative (not US Food and Drug Administration&ndash;approved) regimens including subcutaneous <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> (200 <span class=\"nowrap\">mcg/kg)</span> [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/119-121\" class=\"abstract_t\">119-121</a>] per rectal ivermectin administration [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/122\" class=\"abstract_t\">122</a>] and a parenteral veterinary formulation of ivermectin [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/123-125\" class=\"abstract_t\">123-125</a>] have been used with variable success. In one case of refractory strongyloidiasis, combined longer-term ivermectin and <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> has been successful [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/126\" class=\"abstract_t\">126</a>]. Ongoing monthly ivermectin for at least six months may be warranted in the setting of ongoing immunosuppression.</p><p>Patients with disseminated <span class=\"nowrap\">disease/hyperinfection</span> that does not resolve after a single treatment course should be evaluated for an underlying immune defect such as human T-lymphotropic virus type I infection. (See <a href=\"topic.htm?path=human-t-lymphotropic-virus-type-i-disease-associations-diagnosis-and-treatment#H22\" class=\"medical medical_review\">&quot;Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment&quot;, section on 'Diagnosis'</a>.)</p><p>Blood cultures should be obtained in the setting of hyperinfection syndrome, and broad-spectrum empiric antibiotics that include coverage of enteric gram-negative bacteria should be administered.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">PATIENT MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who are being treated for strongyloidiasis should have follow-up stool examinations, complete blood counts with eosinophilia, and serologies.</p><p>Treatment failures may occur even with <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> in nonimmunocompromised hosts. If stool exams were positive for larvae prior to treatment, repeat stool exams should be performed about two to four weeks after treatment. In the setting of the hyperinfection syndrome, treatment should be administered until symptoms resolve and daily stool examinations have been negative for at least two weeks. However, a negative stool exam is not definitive proof of parasitologic cure since stool exams are insensitive for detecting larvae. Persistent symptoms following treatment for strongyloidiasis should raise the possibility that initial ivermectin treatment was not fully curative.</p><p>Decreasing titers of anti-<em>Strongyloides </em>antibodies may also be useful to assess treatment adequacy of treatment; we recommend repeat serologies at three to six months [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/127\" class=\"abstract_t\">127</a>]. One retrospective study of 31 patients treated for strongyloidiasis noted a significant reduction in blood eosinophilia and serologic antibody titer after an average of 96 and 270 days, respectively [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/79\" class=\"abstract_t\">79</a>]. In another study among Cambodian refugees, 65 percent of patients followed with serial serology reached levels consistent with cure 6 to 12 months after treatment [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/128\" class=\"abstract_t\">128</a>]. Eosinophilia persisting for several months after treatment suggests either failure to eradicate strongyloides <span class=\"nowrap\">and/or</span> other etiologies for eosinophilia [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/110\" class=\"abstract_t\">110</a>]. (See <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prognosis of strongyloidiasis is good except in the hyperinfection syndrome. The latter patients have high case-fatality rates that are increased by concomitant immunosuppression, bacteremia, and delayed diagnosis [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/129\" class=\"abstract_t\">129</a>]. Failure to respond to <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> raises the possibility that the patient has underlying human T-lymphotropic virus type I [<a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/130,131\" class=\"abstract_t\">130,131</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevention of strongyloidiasis in endemic areas is mainly achieved by wearing shoes in order to avoid contact with infected soil.</p><p>Patients with latent <em>S. stercoralis</em> infection who are about to begin immunosuppressive therapy are at risk for disseminated <span class=\"nowrap\">disease/hyperinfection</span> syndrome, which can be fatal. Therefore, evaluation for <em>Strongyloides</em> infection is warranted for patients with epidemiologic risk (rural exposure in tropics, subtropics, Appalachia, and southern Europe, including military service). Data on the optimal approach to prevention are limited. In general, we favor the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who require prompt initiation of immunosuppression, serologic testing should be performed; empiric treatment for prevention of strongyloidiasis may be administered (<a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> 200 <span class=\"nowrap\">mcg/kg</span> daily for two days) while serologic test results are pending. If serologic test results are found to be positive and the patient subsequently develops clinical manifestations consistent with hyperinfection syndrome, there should be a low threshold to administer repeat ivermectin therapy. (See <a href=\"#H21\" class=\"local\">'Disseminated disease/hyperinfection syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who do not require prompt initiation of immunosuppression (ie, there is sufficient time to pursue screening), serologic testing is appropriate. In the setting of high suspicion (ie, substantial epidemiologic exposure with presence of eosinophilia), stool examination (at least two concentrated specimens) for the presence of rhabditiform larvae is also appropriate. If either or both are positive, empiric treatment for prevention of strongyloidiasis (<a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> 200 <span class=\"nowrap\">mcg/kg</span> daily for two days) is appropriate; if both serology and stool examination are negative, no empiric treatment is necessary.</p><p/><p>In addition, there is risk for donor-derived strongyloidiasis among solid organ transplant recipients receiving organs from donors with epidemiologic risk for latent <em>Strongyloides</em> infection. Such donors should undergo serologic testing for strongyloidiasis, and detection of donor <em>Strongyloides </em>infection should prompt administration of strongyloidiasis prophylaxis (<a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> 200 <span class=\"nowrap\">mcg/kg</span> daily for two days) to the organ recipient at the time of transplantation.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strongyloidiasis is endemic in tropical and subtropical regions and occurs sporadically in temperate areas. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The burden of adult worms in infected humans can increase substantially via autoinfection. Among immunocompromised hosts, autoinfection can lead to the hyperinfection syndrome where there is massive dissemination of filariform larvae to the lungs, liver, heart, central nervous system, and endocrine glands. (See <a href=\"#H3\" class=\"local\">'Life cycle'</a> above and <a href=\"#H9\" class=\"local\">'Hyperinfection syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most infected patients do not experience prominent symptoms. The most common manifestations are mild waxing and waning gastrointestinal, cutaneous, or pulmonary symptoms that persist for years; others simply have eosinophilia in the absence of symptoms. (See <a href=\"#H5\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For diagnosis, examination of at least two concentrated stool specimens for the presence of rhabditiform larvae should be pursued in addition to serologic testing. If these diagnostic tests are negative and clinical suspicion of strongyloidiasis remains, examination of duodenal fluid for larvae may be pursued; alternatively, empiric <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> therapy may be administered. (See <a href=\"#H12\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend treatment with <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> for uncomplicated strongyloidiasis (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). Ivermectin is usually administered as two single 200 <span class=\"nowrap\">mcg/kg</span> doses administered on two consecutive days. (See <a href=\"#H19\" class=\"local\">'Ivermectin'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with disseminated disease (hyperinfection syndrome), we suggest extended dosing of <a href=\"topic.htm?path=ivermectin-drug-information\" class=\"drug drug_general\">ivermectin</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). The typical dose schedule is 200 <span class=\"nowrap\">mcg/kg</span> daily for at least five to seven days. Ivermectin can also be combined with <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a>. Daily stool examinations should be performed during treatment to determine the effect on larval burden, and treatment should be administered daily until symptoms resolve and stool tests have been negative for at least two weeks. (See <a href=\"#H21\" class=\"local\">'Disseminated disease/hyperinfection syndrome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with epidemiologic risk for <em>Strongyloides</em> infection who are about to begin immunosuppressive therapy warrant screening or empiric treatment for <em>Strongyloides</em> infection. (See <a href=\"#H24\" class=\"local\">'Prevention'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with eosinophilia that persists for more than three months despite therapy, we recommend evaluation for treatment failure or other causes of eosinophilia. (See <a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">&quot;Approach to the patient with unexplained eosinophilia&quot;</a>.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/1\" class=\"nounderline abstract_t\">Sch&auml;r F, Trostdorf U, Giardina F, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis 2013; 7:e2288.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/2\" class=\"nounderline abstract_t\">Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections. Lancet 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/3\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention. Notes from the field: Strongyloidiasis in a rural setting--Southeastern Kentucky, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:843.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/4\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention. Notes from the field: strongyloides infection among patients at a long-term care facility--Florida, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62:844.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/5\" class=\"nounderline abstract_t\">Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/6\" class=\"nounderline abstract_t\">Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol 1990; 132:257.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/7\" class=\"nounderline abstract_t\">Jones JM, Hill C, Briggs G, et al. Notes from the Field: Strongyloidiasis at a Long-Term-Care Facility for the Developmentally Disabled - Arizona, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:608.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/8\" class=\"nounderline abstract_t\">Kim JH, Kim DS, Yoon YK, et al. Donor-Derived Strongyloidiasis Infection in Solid Organ Transplant Recipients: A Review and Pooled Analysis. Transplant Proc 2016; 48:2442.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/9\" class=\"nounderline abstract_t\">Abanyie FA, Gray EB, Delli Carpini KW, et al. Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009-2013. Am J Transplant 2015; 15:1369.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/10\" class=\"nounderline abstract_t\">Schupf N, Ortiz M, Kapell D, et al. Prevalence of intestinal parasite infections among individuals with mental retardation in New York State. Ment Retard 1995; 33:84.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/11\" class=\"nounderline abstract_t\">Lindo JF, Robinson RD, Terry SI, et al. Age-prevalence and household clustering of Strongyloides stercoralis infection in Jamaica. Parasitology 1995; 110 ( Pt 1):97.</a></li><li class=\"breakAll\">Siddiqui AA, Genta RM, Berk SL. Chapter 111. In: Infectious Diseases - Principles, Practices and Pathogens, Guerrant RL, Walker DH, Weller PF (Eds), Churchhill-Livingstone Elsevier, Philadelphia 2006. p.1274.</li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/13\" class=\"nounderline abstract_t\">Chu E, Whitlock WL, Dietrich RA. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 1990; 97:1475.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/14\" class=\"nounderline abstract_t\">Pelletier LL Jr, Baker CB, Gam AA, et al. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 1988; 157:573.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/15\" class=\"nounderline abstract_t\">Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17:208.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/16\" class=\"nounderline abstract_t\">Haque AK, Schnadig V, Rubin SA, Smith JH. Pathogenesis of human strongyloidiasis: autopsy and quantitative parasitological analysis. Mod Pathol 1994; 7:276.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/17\" class=\"nounderline abstract_t\">Nutman TB, Ottesen EA, Ieng S, et al. Eosinophilia in Southeast Asian refugees: evaluation at a referral center. J Infect Dis 1987; 155:309.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/18\" class=\"nounderline abstract_t\">Arsi&#263;-Arsenijevi&#263; V, Dzami&#263; A, Dzami&#263; Z, et al. Fatal Strongyloides stercoralis infection in a young woman with lupus glomerulonephritis. J Nephrol 2005; 18:787.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/19\" class=\"nounderline abstract_t\">Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169:692.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/20\" class=\"nounderline abstract_t\">Mackey SL, Wagner KF. Dermatologic manifestations of parasitic diseases. Infect Dis Clin North Am 1994; 8:713.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/21\" class=\"nounderline abstract_t\">Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol 2003; 21:407.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/22\" class=\"nounderline abstract_t\">ARTHUR RP, SHELLEY WB. Larva currens; a distinctive variant of cutaneous larva migrans due to Strongyloides stercoralis. AMA Arch Derm 1958; 78:186.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/23\" class=\"nounderline abstract_t\">Salluh JI, Bozza FA, Pinto TS, et al. Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease? Braz J Infect Dis 2005; 9:419.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/24\" class=\"nounderline abstract_t\">Reddy TS, Myers JW. Syndrome of inappropriate secretion of antidiuretic hormone and nonpalpable purpura in a woman with Strongyloides stercoralis hyperinfection. Am J Med Sci 2003; 325:288.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/25\" class=\"nounderline abstract_t\">Van Dellen RG, Maddox DE, Dutta EJ. Masqueraders of angioedema and urticaria. Ann Allergy Asthma Immunol 2002; 88:10.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/26\" class=\"nounderline abstract_t\">Mehta RK, Shah N, Scott DG, et al. Case 4. Chronic urticaria due to strongyloidiasis. Clin Exp Dermatol 2002; 27:84.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/27\" class=\"nounderline abstract_t\">Ly MN, Bethel SL, Usmani AS, Lambert DR. Cutaneous Strongyloides stercoralis infection: an unusual presentation. J Am Acad Dermatol 2003; 49:S157.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/28\" class=\"nounderline abstract_t\">Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57:527.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/29\" class=\"nounderline abstract_t\">Berkmen YM, Rabinowitz J. Gastrointestinal manifestations of the stongyloidiasis. Am J Roentgenol Radium Ther Nucl Med 1972; 115:306.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/30\" class=\"nounderline abstract_t\">Sen P, Gil C, Estrellas B, Middleton JR. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South Med J 1995; 88:923.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/31\" class=\"nounderline abstract_t\">Wehner JH, Kirsch CM, Kagawa FT, et al. The prevalence and response to therapy of Strongyloides stercoralis in patients with asthma from endemic areas. Chest 1994; 106:762.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/32\" class=\"nounderline abstract_t\">Lin AL, Kessimian N, Benditt JO. Restrictive pulmonary disease due to interlobular septal fibrosis associated with disseminated infection by Strongyloides stercoralis. Am J Respir Crit Care Med 1995; 151:205.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/33\" class=\"nounderline abstract_t\">Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 2005; 128:3681.</a></li><li class=\"breakAll\">Longworth DL, Weller PF. Hyperinfection syndrome with strongyloidiasis. In: Current Clinical Topics in Infectious Diseases, Remington JS, Swartz MN (Eds), McGraw-Hill, New York 1986. p.1.</li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/35\" class=\"nounderline abstract_t\">Woodring JH, Halfhill H 2nd, Reed JC. Pulmonary strongyloidiasis: clinical and imaging features. AJR Am J Roentgenol 1994; 162:537.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/36\" class=\"nounderline abstract_t\">Cebular S, Lee S, Tolaney P, Lutwick L. Community-acquired pneumonia in immunocompromised patients. Opportunistic infections to consider in differential diagnosis. Postgrad Med 2003; 113:65.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/37\" class=\"nounderline abstract_t\">Strazzella WD, Safirstein BH. Asthma due to parasitic infestation. N J Med 1989; 86:947.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/38\" class=\"nounderline abstract_t\">Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/39\" class=\"nounderline abstract_t\">Nwokolo C, Imohiosen EA. Strongyloidiasis of respiratory tract presenting as &quot;asthma&quot;. Br Med J 1973; 2:153.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/40\" class=\"nounderline abstract_t\">Ghoshal UC, Ghoshal U, Jain M, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 2002; 17:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/41\" class=\"nounderline abstract_t\">Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005; 40:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/42\" class=\"nounderline abstract_t\">Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant 2004; 23:905.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/43\" class=\"nounderline abstract_t\">Adam M, Morgan O, Persaud C, Gibbs WN. Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma. Br Med J 1973; 1:264.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/44\" class=\"nounderline abstract_t\">Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med 1966; 275:1093.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/45\" class=\"nounderline abstract_t\">Higenbottam TW, Heard BE. Opportunistic pulmonary strongyloidiasis complicating asthma treated with steroids. Thorax 1976; 31:226.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/46\" class=\"nounderline abstract_t\">Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med 1974; 56:488.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/47\" class=\"nounderline abstract_t\">Smith SB, Schwartzman M, Mencia LF, et al. Fatal disseminated strongyloidiasis presenting as acute abdominal distress in an urban child. J Pediatr 1977; 91:607.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/48\" class=\"nounderline abstract_t\">Stemmermann GN. Strongyloidiasis in migrants. Pathological and clinical considerations. Gastroenterology 1967; 53:59.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/49\" class=\"nounderline abstract_t\">Davidson RA. Infection due to Strongyloides stercoralis in patients with pulmonary disease. South Med J 1992; 85:28.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/50\" class=\"nounderline abstract_t\">Safdar A, Malathum K, Rodriguez SJ, et al. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 2004; 100:1531.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/51\" class=\"nounderline abstract_t\">Lemos LB, Qu Z, Laucirica R, Fred HL. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann Diagn Pathol 2003; 7:87.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/52\" class=\"nounderline abstract_t\">Hira PR, Al-Ali F, Shweiki HM, et al. Strongyloidiasis: challenges in diagnosis and management in non-endemic Kuwait. Ann Trop Med Parasitol 2004; 98:261.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/53\" class=\"nounderline abstract_t\">Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/54\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Transmission of Strongyloides stercoralis through transplantation of solid organs--Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:264.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/55\" class=\"nounderline abstract_t\">Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/56\" class=\"nounderline abstract_t\">Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol 2005; 39:203.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/57\" class=\"nounderline abstract_t\">Schad GA. Cyclosporine may eliminate the threat of overwhelming strongyloidiasis in immunosuppressed patients. J Infect Dis 1986; 153:178.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/58\" class=\"nounderline abstract_t\">Porto MA, Alc&acirc;ntara LM, Leal M, et al. Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T cell lymphotrophic virus type I. Am J Trop Med Hyg 2005; 72:124.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/59\" class=\"nounderline abstract_t\">Satoh M, Kiyuna S, Shiroma Y, et al. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol 2003; 133:391.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/60\" class=\"nounderline abstract_t\">Rahim S, Drabu Y, Jarvis K, Melville D. Strongyloidiasis: a mistaken diagnosis and a fatal outcome in a patient with diarrhoea. Trans R Soc Trop Med Hyg 2005; 99:215.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/61\" class=\"nounderline abstract_t\">Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26:487.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/62\" class=\"nounderline abstract_t\">Plumelle Y, Pascaline N, Nguyen D, et al. Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique. Hematol Pathol 1993; 7:251.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/63\" class=\"nounderline abstract_t\">Montes M, Sanchez C, Verdonck K, et al. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009; 3:e456.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/64\" class=\"nounderline abstract_t\">Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/65\" class=\"nounderline abstract_t\">Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/66\" class=\"nounderline abstract_t\">Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome. Clin Infect Dis 2004; 39:439.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/67\" class=\"nounderline abstract_t\">Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS 2007; 21:649.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/68\" class=\"nounderline abstract_t\">Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/69\" class=\"nounderline abstract_t\">Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190:2175.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/70\" class=\"nounderline abstract_t\">Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/71\" class=\"nounderline abstract_t\">Sathiyasekaran M, Shibalan S. Intestinal strongyloidiasis and common variable immunodeficiency syndrome. Indian Pediatr 2005; 42:391.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/72\" class=\"nounderline abstract_t\">Boatright MD, Wang BW. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum 2005; 52:1336.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/73\" class=\"nounderline abstract_t\">Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol 2007; 13:150.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/74\" class=\"nounderline abstract_t\">Marty FM. Strongyloides hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. Transpl Infect Dis 2009; 11:97.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/75\" class=\"nounderline abstract_t\">Vilela EG, Clemente WT, Mira RR, et al. Strongyloides stercoralis hyperinfection syndrome after liver transplantation: case report and literature review. Transpl Infect Dis 2009; 11:132.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/76\" class=\"nounderline abstract_t\">Valar C, Keitel E, Dal Pr&aacute; RL, et al. Parasitic infection in renal transplant recipients. Transplant Proc 2007; 39:460.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/77\" class=\"nounderline abstract_t\">Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012; 25:458.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/78\" class=\"nounderline abstract_t\">Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/79\" class=\"nounderline abstract_t\">Nuesch R, Zimmerli L, Stockli R, et al. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005; 12:80.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/80\" class=\"nounderline abstract_t\">Gill GV, Welch E, Bailey JW, et al. Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. QJM 2004; 97:789.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/81\" class=\"nounderline abstract_t\">Johnston FH, Morris PS, Speare R, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health 2005; 13:247.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/82\" class=\"nounderline abstract_t\">Lim S, Katz K, Krajden S, et al. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004; 171:479.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/83\" class=\"nounderline abstract_t\">Agrawal V, Agarwal T, Ghoshal UC. Intestinal strongyloidiasis: a diagnosis frequently missed in the tropics. Trans R Soc Trop Med Hyg 2009; 103:242.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/84\" class=\"nounderline abstract_t\">Al-Hasan MN, McCormick M, Ribes JA. Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. Am J Clin Pathol 2007; 128:622.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/85\" class=\"nounderline abstract_t\">Beal CB, Viens P, Grant RG, Hughes JM. A new technique for sampling duodenal contents: demonstration of upper small-bowel pathogens. Am J Trop Med Hyg 1970; 19:349.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/86\" class=\"nounderline abstract_t\">Boulware DR, Stauffer WM 3rd, Walker PF. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008; 358:2839; author reply 2839.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/87\" class=\"nounderline abstract_t\">Rosenblatt JE. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis 2006; 42:979.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/88\" class=\"nounderline abstract_t\">Hirata T, Nakamura H, Kinjo N, et al. Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method. Am J Trop Med Hyg 2007; 77:683.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/89\" class=\"nounderline abstract_t\">Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10:105.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/90\" class=\"nounderline abstract_t\">Greiner K, Bettencourt J, Semolic C. Strongyloidiasis: a review and update by case example. Clin Lab Sci 2008; 21:82.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/91\" class=\"nounderline abstract_t\">Eveland LK, Kenney M, Yermakov V. Laboratory diagnosis of autoinfection in strongyloidiasis. Am J Clin Pathol 1975; 63:421.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/92\" class=\"nounderline abstract_t\">Schainberg L, Scheinberg MA. Recovery of Strongyloides stercoralis by bronchoalveolar lavage in a patient with acquired immunodeficiency syndrome. Am J Med 1989; 87:486.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/93\" class=\"nounderline abstract_t\">Smith B, Verghese A, Guiterrez C, et al. Pulmonary strongyloidiasis. Diagnosis by sputum gram stain. Am J Med 1985; 79:663.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/94\" class=\"nounderline abstract_t\">Williams J, Nunley D, Dralle W, et al. Diagnosis of pulmonary strongyloidiasis by bronchoalveolar lavage. Chest 1988; 94:643.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/95\" class=\"nounderline abstract_t\">Harris RA Jr, Musher DM, Fainstein V, et al. Disseminated strongyloidiasis. Diagnosis made by sputum examination. JAMA 1980; 244:65.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/96\" class=\"nounderline abstract_t\">Abdalla J, Saad M, Myers JW, Moorman JP. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 2005; 40:1464, 1535.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/97\" class=\"nounderline abstract_t\">Assar&eacute; RK, H&uuml;rlimann E, Ouattara M, et al. Sustaining the Control of Schistosoma mansoni in Western C&ocirc;te d'Ivoire: Baseline Findings Before the Implementation of a Randomized Trial. Am J Trop Med Hyg 2016; 94:352.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/98\" class=\"nounderline abstract_t\">Sharifdini M, Mirhendi H, Ashrafi K, et al. Comparison of Nested Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction with Parasitological Methods for Detection of Strongyloides stercoralis in Human Fecal Samples. Am J Trop Med Hyg 2015; 93:1285.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/99\" class=\"nounderline abstract_t\">Carroll SM, Karthigasu KT, Grove DI. Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 1981; 75:706.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/100\" class=\"nounderline abstract_t\">Neva FA, Gam AA, Burke J. Comparison of larval antigens in an enzyme-linked immunosorbent assay for strongyloidiasis in humans. J Infect Dis 1981; 144:427.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/101\" class=\"nounderline abstract_t\">Savage D, Foadi M, Haworth C, Grant A. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis. J Intern Med 1994; 236:473.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/102\" class=\"nounderline abstract_t\">van Doorn HR, Koelewijn R, Hofwegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/103\" class=\"nounderline abstract_t\">Boscolo M, Gobbo M, Mantovani W, et al. Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin Vaccine Immunol 2007; 14:129.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/104\" class=\"nounderline abstract_t\">Ramanathan R, Burbelo PD, Groot S, et al. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 2008; 198:444.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/105\" class=\"nounderline abstract_t\">Sreenivas DV, Kumar A, Kumar YR, et al. Intestinal strongyloidiasis--a rare opportunistic infection. Indian J Gastroenterol 1997; 16:105.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/106\" class=\"nounderline abstract_t\">Thompson BF, Fry LC, Wells CD, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc 2004; 59:906.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/107\" class=\"nounderline abstract_t\">Overstreet K, Chen J, Rodriguez JW, Wiener G. Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS. Gastrointest Endosc 2003; 58:928.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/108\" class=\"nounderline abstract_t\">Qu Z, Kundu UR, Abadeer RA, Wanger A. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 2009; 40:572.</a></li><li class=\"breakAll\">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/110\" class=\"nounderline abstract_t\">Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/111\" class=\"nounderline abstract_t\">Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016; :CD007745.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/112\" class=\"nounderline abstract_t\">Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002; 8:94.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/113\" class=\"nounderline abstract_t\">Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996; 55:477.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/114\" class=\"nounderline abstract_t\">Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med 1993; 86:191.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/115\" class=\"nounderline abstract_t\">Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 2004; 132:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/116\" class=\"nounderline abstract_t\">Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008; 31:46.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/117\" class=\"nounderline abstract_t\">Barda B, Sayasone S, Phongluxa K, et al. Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial. Clin Infect Dis 2017; 65:276.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/118\" class=\"nounderline abstract_t\">Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007; 41:1992.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/119\" class=\"nounderline abstract_t\">Pacanowski J, Santos MD, Roux A, et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg 2005; 73:122.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/120\" class=\"nounderline abstract_t\">Leung V, Al-Rawahi GN, Grant J, et al. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am J Trop Med Hyg 2008; 79:853.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/121\" class=\"nounderline abstract_t\">Turner SA, Maclean JD, Fleckenstein L, Greenaway C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 2005; 73:911.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/122\" class=\"nounderline abstract_t\">Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003; 68:453.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/123\" class=\"nounderline abstract_t\">Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005; 41:e5.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/124\" class=\"nounderline abstract_t\">Salluh JI, Feres GA, Velasco E, et al. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. Intensive Care Med 2005; 31:1292.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/125\" class=\"nounderline abstract_t\">Miller MA, Church LW, Salgado CD. Strongyloides hyperinfection: a treatment dilemma. Am J Med Sci 2008; 336:358.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/126\" class=\"nounderline abstract_t\">Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004; 35:531.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/127\" class=\"nounderline abstract_t\">Kobayashi J, Sato Y, Toma H, et al. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 1994; 18:19.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/128\" class=\"nounderline abstract_t\">Biggs BA, Caruana S, Mihrshahi S, et al. Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful? Am J Trop Med Hyg 2009; 80:788.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/129\" class=\"nounderline abstract_t\">El Masry HZ, O'Donnell J. Fatal stongyloides hyperinfection in heart transplantation. J Heart Lung Transplant 2005; 24:1980.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/130\" class=\"nounderline abstract_t\">Terashima A, Alvarez H, Tello R, et al. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis 2002; 6:28.</a></li><li><a href=\"https://www.uptodate.com/contents/strongyloidiasis/abstract/131\" class=\"nounderline abstract_t\">Jeyamani R, Joseph AJ, Chacko A. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection. Trop Gastroenterol 2007; 28:176.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5714 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H25\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">LIFE CYCLE</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Autoinfection</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Skin reactions</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Gastrointestinal symptoms</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Pulmonary manifestations</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Hyperinfection syndrome</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Role of immunosuppression</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">WHOM TO TEST</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">DIAGNOSIS</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Detection of larvae</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Serology</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Endoscopy</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">TREATMENT</a><ul><li><a href=\"#H18\" id=\"outline-link-H18\">Uncomplicated infection</a><ul><li><a href=\"#H19\" id=\"outline-link-H19\">- Ivermectin</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Albendazole</a></li><li><a href=\"#H2967228659\" id=\"outline-link-H2967228659\">- Other</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">Disseminated disease/hyperinfection syndrome</a></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">PATIENT MONITORING</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">PROGNOSIS</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">PREVENTION</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5714|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/97783\" class=\"graphic graphic_diagnosticimage\">- Imaging pulmonary strongyloides</a></li></ul></li><li><div id=\"ID/5714|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/87284\" class=\"graphic graphic_figure\">- Strongyloides life cycle</a></li></ul></li><li><div id=\"ID/5714|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/63898\" class=\"graphic graphic_picture\">- Strongyloides in stool</a></li><li><a href=\"image.htm?imageKey=ID/51753\" class=\"graphic graphic_picture\">- Endoscopy - strongyloidiasis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-stool-microscopy\" class=\"medical medical_review\">Approach to stool microscopy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-unexplained-eosinophilia\" class=\"medical medical_review\">Approach to the patient with unexplained eosinophilia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hookworm-related-cutaneous-larva-migrans\" class=\"medical medical_review\">Hookworm-related cutaneous larva migrans</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-t-lymphotropic-virus-type-i-disease-associations-diagnosis-and-treatment\" class=\"medical medical_review\">Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tropical-pulmonary-eosinophilia\" class=\"medical medical_review\">Tropical pulmonary eosinophilia</a></li></ul></div></div>","javascript":null}